These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11023518)

  • 41. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.
    Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Osterborg A; Mellstedt H
    Int J Cancer; 1999 Mar; 80(5):671-80. PubMed ID: 10048965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA.
    Milazzo C; Reichardt VL; Müller MR; Grünebach F; Brossart P
    Blood; 2003 Feb; 101(3):977-82. PubMed ID: 12393470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
    Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
    Lauritzsen GF; Bogen B
    Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.
    Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
    Br J Haematol; 1996 Mar; 92(4):840-6. PubMed ID: 8616076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
    Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
    Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
    Foglietta M; Neelapu SS; Kwak LW; Jiang Y; Nattamai D; Lee ST; Fowler DH; Sportes C; Gress RE; Steinberg SM; Vence LM; Radvanyi L; Dwyer KC; Qazilbash MH; Bryant RN; Bishop MR
    Bone Marrow Transplant; 2013 Feb; 48(2):269-77. PubMed ID: 22773122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma.
    Wen YJ; Ling M; Lim SH
    Br J Haematol; 1998 Mar; 100(3):464-8. PubMed ID: 9504627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cells in clinical trials for multiple myeloma.
    Reichardt VL; Brossart P
    Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
    Meehan KR; Talebian L; Tosteson TD; Hill JM; Szczepiorkowski Z; Sentman CL; Ernstoff MS
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):129-37. PubMed ID: 22975165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes.
    Szea DM; Brown RD; Yang S; Gibson J; Ho J; Fazekas de St Groth B; Basten A; Joshua DE
    Leuk Lymphoma; 2003 Sep; 44(9):1557-68. PubMed ID: 14565660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. H-2-linked Ir gene control of VH determinant(s)-specific helper T cells.
    Kawahara DJ; Marrack P; Kappler JW
    J Mol Cell Immunol; 1986; 2(5):255-64. PubMed ID: 2978232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.
    Leaf RK; Stroopinsky D; Pyzer AR; Kruisbeek AM; van Wetering S; Washington A; Ephraim A; Cole L; Morin A; Jain S; Nahas MR; Apel A; Arnason J; Hamdan A; Rosenblatt J; Avigan D
    J Immunother; 2017; 40(9):315-322. PubMed ID: 28961609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
    Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M; Ochi A
    J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules.
    Yi Q; Holm G; Lefvert AK
    Clin Exp Immunol; 1996 May; 104(2):359-65. PubMed ID: 8625533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.